| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | NCAN |
| Uniprot No | O14594 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 81-179aa |
| 氨基酸序列 | VRTASGQRQDLPILVAKDNVVRVAKSWQGRVSLPSYPRRRANATLLLGPL RASDSGLYRCQVVRGIEDEQDLVPLEVTGVVFHYRSARDRYALTFAEAQ |
| 预测分子量 | 37 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于NCAN(Neurocan)重组蛋白的3篇示例参考文献，供您参考。建议通过学术数据库(如PubMed、Google Scholar)进一步检索以获取详细信息：
---
1. **标题**: *Neurocan inhibits axonal growth by interaction with neuronal cell surface receptors*
**作者**: Asher, R.A., Morgenstern, D.A., Fidler, P.S. et al.
**期刊**: *Journal of Biological Chemistry* (2005)
**摘要**: 研究报道了通过重组NCAN蛋白探究其对神经元轴突生长的调控作用。实验发现，重组NCAN可与神经元表面的特定受体(如整合素)结合，抑制轴突延伸，提示其在神经发育和损伤修复中的潜在功能。
---
2. **标题**: *Structural and functional analysis of recombinant neurocan domains*
**作者**: Milev, P., Friederichs, S., Maurel, P. et al.
**期刊**: *Journal of Neuroscience Research* (1998)
**摘要**: 本研究通过重组表达NCAN的不同结构域(如N端和C端片段)，分析其结构特征(如糖基化修饰)与功能。发现C端结构域在细胞黏附和信号转导中起关键作用。
---
3. **标题**: *Neurocan interacts with growth factor receptors to modulate synaptic plasticity*
**作者**: Rauch, U., Zhou, X.H., Roos, G.
**期刊**: *Molecular and Cellular Neuroscience* (2001)
**摘要**: 利用重组NCAN蛋白探究其与生长因子受体(如FGFR)的相互作用。结果表明，NCAN通过调控受体活性影响突触可塑性和神经再生，为神经退行性疾病研究提供新视角。
---
**备注**：以上文献为示例性质，实际检索时建议结合具体关键词(如“recombinant Neurocan”、“NCAN expression”)在学术平台查询最新研究。如需全文链接或更多文献，请进一步说明需求。
**Background of NCAN Recombinant Protein**
Neurocan (NCAN), a chondroitin sulfate proteoglycan (CSPG), belongs to the lectican family of extracellular matrix (ECM) proteins. It is predominantly expressed in the central nervous system (CNS) during development, playing critical roles in neuronal adhesion, axon guidance, and synaptic plasticity. Structurally, NCAN consists of an N-terminal hyaluronan-binding domain, a central chondroitin sulfate (CS)-modified region, and a C-terminal lectin-like domain, enabling interactions with ECM components and cell surface receptors.
Recombinant NCAN protein is engineered to study its biological functions *in vitro* or *in vivo*. Produced via heterologous expression systems (e.g., mammalian or insect cells), it retains post-translational modifications, such as glycosylation, essential for its activity. Researchers utilize recombinant NCAN to investigate its involvement in neural development, neurodegeneration (e.g., Alzheimer’s disease), and psychiatric disorders (e.g., schizophrenia), as genome-wide studies link *NCAN* gene variants to bipolar disorder.
Additionally, NCAN’s role in modulating growth factor signaling (e.g., BDNF) and ECM remodeling highlights its therapeutic potential. Recombinant NCAN serves as a tool to explore mechanisms in CNS repair, tumor microenvironment regulation, and tissue engineering. Challenges in its application include maintaining structural integrity during purification and addressing its dual roles in neuroprotection versus inhibition of neural regeneration. Current studies focus on deciphering NCAN’s context-dependent interactions and developing targeted strategies for neurological and psychiatric therapies.
This recombinant protein thus bridges molecular insights into CSPG biology and translational research, offering avenues for diagnostics and treatment development.
×
